Glioblastoma — biological & vaccine options

Prefer to look first? Browse the live map without signing up.

10 open options

TRIALPHASE1RECRUITING
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
NK cells — 1 site
TRIALPHASE1 / PHASE2RECRUITING
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
EBNK-001 + IL-15 + Pembrolizumab — 1 site
TRIALEARLY_PHASE1ENROLLING_BY_INVITATION
Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma
mRNA vaccine: GV-907、GV-108 — 1 site
TRIALPHASE1RECRUITING
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Dual-target CAR-NK cells · Cyclophosphamide · Intracranial catheter/reservoir for locoregional delivery — 1 site
TRIALPHASE1 / PHASE2RECRUITING
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Near-Infrared Fluorescence Imaging · Panitumumab · Panitumumab-IRDye800 — 1 site
TRIALPHASE1RECRUITING
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
G207 — 3 sites
TRIALNANOT_YET_RECRUITING
Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma
CHANK-101 — 4 sites
TRIALPHASE1 / PHASE2RECRUITING
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
P134 cell injection — 1 site
TRIALPHASE2RECRUITING
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
PEP-CMV · Temozolomide · Tetanus Diphtheria Vaccine — 13 sites
TRIALNARECRUITING
Control Cohort CTRL COH
Collection of biological sample (blood and/or CSF) — 1 site

Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.